Visual Field Testing


Description:
Visual field testing is a process to determine defects in the field of vision and tests
the function of the retina, optic nerve and optic pathways. The process may include simple
confrontation (not reimbursable) to increasingly complex studies with sophisticated
equipment.

Indications and Limitations of Coverage and/or Medical Necessity:
The following diagnoses are covered procedures only for the limited visual field examination (CPT 92081):

374.30 - 374.34 Ptosis of eyelid
374.87 Dermatochalasis

The lowest level of testing which is medically necessary must be utilized.

Visual field testing is covered for diagnois and treatment of abnormal signs, symptoms, disease or injury. Documentation in the record must establish medical necessity for the service including the frequency of the service.

There must always be a reason for performing the test since routine exams are not covered or medically necessary.

CPT/HCPCS Section: Special opthalmological services

CPT/HCPCS Codes:

92081 Visual field examination(s)
92082 Visual field examination(s)
92083 Visual field examination(s)

ICD-Codes that Support Medical Necessity:
The use of these ICD-9 codes does not abrogate the requirement that medical necessity be documented in the patient's record.

094.83 - 094.85 Syphilitic retinochoroiditis, optic atrophy, and retrobulbar neuritis
095.0 Syphilitic episcleritis
190.0 - 190.9 Malignant neoplasm of eye
191.0 Malignant neoplasm of cerebrum, except lobes and ventricles
192.0 Malignant neoplasm of cranial nerves
194.3 Malignant neoplasm pituitary gland and craniopharyngeal duct
198.4 Secondary malignant neoplasm, other parts of nervous system
198.89 Secondary malignant neoplasm of other specified sites (04/15/1998)
224.0 - 224.9 Benign neoplasm of eye
225.1 Benign neoplasm of cranial nerves
227.3 Benign neoplasm of pituitary gland and carniopharyngeal duct (pouch) (04/15/1998)
234.0 Carcinoma in situ of eye
237.0 Neoplasm of uncertain behavior of pituitary gland and rainopharyngeal duct (04/15/98)
237.70 - 237.9 Neoplasm, uncertain behavior, nervous system
238.8 Neoplasm of uncertain behavior, other specified sites (eye)
239.6 Neoplasm of unspecified nature, brain
239.8 Neoplasm of unspecified nature, other specified sites
242.00 - 242.01 Toxic diffuse goiter
259.8 Other specified endocrine disorders
300.11 Conversion disorder, blindness
346.00 - 346.91 Migraine
348.2 Benign intracranial hypertension
360.23 Siderosis
360.29 Other degenerative disorders of globe
361.10 - 361.12 Retinoschisis
362.01 - 362.9 Other retinal disorders
363.10 - 363.15 Disseminated chorioretinitis and desseminated retinochoroiditis (12/04/1997)
363.20 - 363.22 Other and unspecified forms of chorioretinitis and retinochoroiditis (12/04/1997)
363.30 - 363.35 Chorioretinal scars (12/04/1997)
363.40 - 363.43 Choroidal degenerations (12/04/1997)
363.50 - 363.57 Hereditary choroidal dystrophies (12/04/1997)
363.61 - 363.63 Choroidal hemorrhage and rupture (12/04/1997)
363.70 - 363.72 Choroidal detachment (12/04/1967)
363.8 Other disorders of choroid (12/04/1997)
363.9 Unspecified disorder of choroid (12/04/1997)
365.00 - 365.9 Glaucoma
368.00 - 368.9 Visual disturbances
369.00 - 369.9 Profound impairment, both eyes
374.30 - 374.34 Ptosis of eyelid (payable only for CPT 92081) (12/04/1997)
374.87 Dermatochalasis (payable only for CPT 92081) (12/04/1997)
376.00 - 376.9 Disorders of the orbit
377.00 - 377.9 Disorders of the optic nerve and visual pathways
378.55 External ophthalmoplegia
437.3 Cerebral aneurysm, nonruptured (12/97)
446.5 Giant cell arteritis (12/29/1997)
743.20 - 743.22 Buphthalmos
743.44 Specified anomalies of anterior chamber, chamber angle, and related structures
743.52 - 743.53 Fundus coloboma to chorioretinal degeneration, congenital
743.55 - 743.59 Congenital macular changes to other congenital anomalies of posterior segment
743.61 Congenital ptosis
950.0 - 950.9 Optic nerve injury to unspecified injury to optic nerve and pathways
995.2 Unspecified adverse effect of drug, medicinal and biological substance
V45.61 - V45.69 Postsurgical states following surgery of eye and adnexa (07/20/98)
V58.63 Long-term (current) use of antiplatelets/antithrombotics (Added 10/01/2003)
V58.64 Long-term (current) use of non-steroidal anti-inflammatories (NSAID)(Added 10/01/2003)
V58.65 Long-term (current) use of steroids (added 10/01/2003)
V58.69 Long term (current) use of other (high-risk) medications (12/97)
V58.83 Encounter for therapeutic drug monitoring (09/19/2000)
V65.2 Person feigning illness
V80.2 Special screening for other eye conditions

Reasons for Denials:
Lack of medical necessity. Screening examination.

Non-covered ICD-9 Codes:
All other diagnosis codes, which are not listed as covered in the "ICD-9-CM Codes that Support Medical Necessity" section of this policy.

Coding Guidelines:
All services are considered bilateral. Modifier 50 is not appropriate.

The beneficiary is not liable for services denied as not reasonable or necessary unless a waiver has been signed. When this has been completed, the GA modifier should be used.

If the service is performed in a hospital inpatient or outpatient setting, the modifier 26 should be used to indicate the professional component.

If the visual field examination is medically necessary following laser therapy, the appropriate ICD-9 code should be billed as diagnosis #1 and V45.6 (status following surgery of eye and adnexa) should be billed as diagnosis #2.

Documentation Requirements:
For EMC users: when submitting a claim requires supporting documentation, this information can be included in the appropriate "narrative" record for your claim submission format.

When two or more examinations are performed per year per beneficiary, documentation indicating the medical necessity for the procedure must be submitted with the claim.